Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 1999-2006
DOI: 10.1200/jco.22.01990 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Silvia Novello und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 548-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435 ). Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. Primary end points were overall survival (OS) and progression-free survival (PFS) per RECIST version 1.1 by blinded independent central review (BICR). Five hundred fifty-nine patients were randomly assigned in the intention-to-treat population (pembrolizumab plus chemotherapy, n = 278; placebo plus chemotherapy, n = 281). The median time from random assignment to data cutoff was 56.9 (range, 49.9-66.2) months. OS and PFS were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% CI], 0.71 [0.59 to 0.85] and 0.62 [0.52 to 0.74]), with 5-year OS rates of 18.4% versus 9.7%, respectively. Toxicity was manageable. Among 55 patients who completed 35 cycles of pembrolizumab, the objective response rate was 90.9% and the 3-year OS rate after completion of 35 cycles (approximately 5 years after random assignment) was 69.5%. Pembrolizumab plus chemotherapy maintained an OS and PFS benefit versus placebo plus chemotherapy in previously untreated, metastatic squamous NSCLC and is a standard-of-care first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy.
- Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, Saint Petersburg, Russia.
- Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
- Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
- Thoracic Oncology, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France.
ORCID-Profile: Silvia Novello, Dariusz M Kowalski, Mahmut Gümüş, Julien Mazières, Jeronimo Rodríguez-Cid, Ying Cheng, Ki Hyeong Lee, Shunichi Sugawara, Andrew G Robinson, Balazs Halmos, Luis Paz-Ares
Zitieren
APA
Novello, S., Kowalski, D. M., Luft, A., Gümüş, M., Vicente, D., Mazières, J., Rodríguez-Cid, J., Tafreshi, A., Cheng, Y., Lee, K. H., Golf, A., Sugawara, S., Robinson, A. G., Halmos, B., Jensen, E., Schwarzenberger, P., Pietanza, M. C., & Paz-Ares, L. (2023). Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology, 41(11), 1999-2006. https://doi.org/10.1200/jco.22.01990
Vancouver
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology. 2023;41(11):1999-2006. doi:10.1200/jco.22.01990
BibTeX
@article{Novello2023,
author = {Novello, Silvia and Kowalski, Dariusz M and Luft, Alexander and Gümüş, Mahmut and Vicente, David and Mazières, Julien and Rodríguez-Cid, Jeronimo and Tafreshi, Ali and Cheng, Ying and Lee, Ki Hyeong and Golf, Alexander and Sugawara, Shunichi and Robinson, Andrew G and Halmos, Balazs and Jensen, Erin and Schwarzenberger, Paul and Pietanza, M Catherine and Paz-Ares, Luis},
title = {Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {11},
pages = {1999--2006},
doi = {10.1200/jco.22.01990}
}
EUVIMED